The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension

Journal of Molecular Medicine

Volumn 79, Issue 1, 2001, Pages 21-29

  Engeli, Stefan ^a   Sharma, Arya M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Adipose tissue; Atrial natriuretic peptide; Hypertension; Obesity; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSINOGEN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; LEPTIN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; RENIN; SODIUM; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; ARTERIAL PRESSURE; BODY MASS; GENE EXPRESSION; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FUNCTION; NATRIURESIS; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION;

ADIPOSE TISSUE; ATRIAL NATRIURETIC FACTOR; HYPERTENSION; MODELS, BIOLOGICAL; OBESITY; PORTRAITS; RENIN-ANGIOTENSIN SYSTEM; RESEARCH PERSONNEL; SODIUM;

EID: 0035089472     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000144     Document Type: Review

References (130)

1. Cardiovascular regulation in obesity-induced hypertension
2. The haemodynamics of obesity: A theoretical analysis
3. The disease burden associated with overweight and obesity
4. Medical hazards of obesity
5. Body-mass index and mortality in a prospective cohort of U.S. adults
6. Annual deaths attributable to obesity in the United States
7. Regional adiposity and morbidity
8. Obesity, the sympathetic nervous system, and essential hypertension
9. The sympathoadrenal system, obesity and hypertension: An overview
10. Central obesity and hypertension: Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects
11. Heredity and obesity-associated hypertension: Impact of hormonal characteristics and left ventricular mass
12. The natriuretic peptide system in obesity-related hypertension: New pathophysiological aspects
13. Mechanisms of disease - Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system
14. Mechanisms of hypertension and kidney disease in obesity
15. Obesity-induced hypertension: New concepts from the emerging biology of obesity
16. Obesity and hypertension
17. Weight gain-induced blood pressure elevation
18. Insulin as a vascular hormone: Implications for the pathophysiology of cardiovascular disease
19. Metabolic syndrome and hypertension: Pathophysiology and molecular basis of insulin resistance
20. Sodium and obesity in the pathogenesis of hypertension
21. Blunted natriuretic response to an acute sodium load in obese hypertensive dogs
22. Salt-regulating hormones in young normotensive obese subjects: Effects of saline load
23. Abnormal pressure natriuresis in the dog model of obesity-induced hypertension
24. Mechanisms of abnormal renal sodium handling in obesity hypertension
25. Sodium balance and hypertension in obese and fatty rats
26. Altered pressure-natriuresis in obese Zucker rats
27. The role of salt in the fall of blood pressure accompanying reduction in obesity
28. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents
29. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults
30. Obesity-induced hypertension: Renal function and systemic hemodynamics
31. Renal denervation attenuates the sodium retention and hypertension associated with obesity
32. Obesity, salt intake, and renal perfusion in healthy humans
33. Renal sympathetic nerve activity is increased in obese Zucker rats
34. Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats
35. Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats
36. Neural mechanisms in human obesity-related hypertension
37. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects
38. Sympathetic activation in obese normotensive subjects
39. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans
40. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure
41. Cardiovascular consequences of obesity: Role of leptin
42. Sympathetic and cardiorenal actions of leptin
43. Receptor-mediated regional sympathetic nerve activation by leptin
44. Renal effects of leptin in normotensive, hypertensive, and obese rats
45. Pivotal role of nitric oxide in the control of blood pressure after leptin administration
46. Chronic leptin infusion increases arterial pressure
47. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice
48. Pathophysiological role of leptin in obesity-related hypertension
49. Is there a role for the ob gene product leptin in essential hypertension?
50. High plasma leptin concentrations in hypertensive men but not in hypertensive women
51. Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index
52. The obese gene product, leptin: Possible role in obesity-related hypertension in adolescents
53. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men
54. Role of sympathetic nervous system and neuropeptides in obesity hypertension
55. Abnormal kidney function as a cause and a consequence of obesity hypertension
56. Distribution of renal medullary hyaluronan in lean and obese rabbits
57. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering
58. Aldosterone in obesity
59. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans
60. ACE, angiotensinogen and obesity: A potential pathway leading to hypertension
61. Angiotensinogen levelsand obesity in four black populations
62. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children
63. Plasma angiotensinogen concentrations in obese patients
64. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension
65. Different gene expression of the RAS in human adipose tissue
66. Development of hypertension in a rat model of diet-induced obesity
67. Hypertension in obese Zucker rats. Role of ang II and adrenergic activity
68. The renin-angiotensin system in the type II diabetic obese Zucker rat
69. Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action
70. Molecular basis of human hypertension: Role of angiotensinogen
71. Association between the angiotensinogen 235T-variant and essential hypertension in whites: A systematic review and methodological appraisal
72. Haplotypes of angiotensinogen in essential hypertension
73. Heritability of angiotensin-converting enzyme and angiotensinogen: A comparison of US blacks and Nigerians
74. Renin, aldosterone and glucagon in the natriuresis of fasting
75. Changes in blood pressure and in vasoactive and volume regulatory hormones during semistarvation in obese subjects
76. Blood pressure and hormone changes associated with weight reduction in the obese
77. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients
78. Aldosterone studies in obese patients with hypertension
79. Effect of weight reduction on the renin-aldosterone axis
80. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women
81. Ambulatory blood pressure and neuroendocrine control after diet-assisted gastric restrictive surgery
82. Physiology and pathophysiology of the adipose tissue renin-angiotensin system
83. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue
84. Consequences of weight cycling in obese spontaneously hypertensive rats
85. Refeeding hypertension in dietary obesity
86. Refeeding hypertension in obese spontaneously hypertensive rats
87. Dietary obesity and weight cycling in rats: A model of stress-induced hypertension?
88. Angiotensinogen-deficient mice with hypotension
89. Genetic deficiency of angiotensinogen produces an impaired urine concentrating ability in mice
90. Angiotensinogen produced by adipose tissue is secreted in blood circulation
91. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity
92. Evidence of AGT and TNF-α secretion by human adipocytes from obese patients
93. Adipose expression of tumor necrosis factor: Direct role in obesity-linked insulin resistance
94. The expression of tumor necrosis factor a in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase
95. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance
96. Tumor necrosis factor α activates angiotensinogen gene expression by the Rel A transactivator
97. Effects of insulin and glucagon on production of renin substrate by the isolated rat liver
98. Downregulation of the renin-angiotensin system in streptozotocin-diabetic rats
99. Differential regulation of leptin and AGT secretion in rat adipose cells
100. Angiotensinogen gene expression in adipose tissue: Analysis of obese models and hormonal and nutritional control
101. Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells
102. Differentiation of preadipose cells: Paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II
103. Mechanisms contributing to angiotensin II regulation of body weight
104. Angiotensin II in brown adipose tissue from young and adult Zucker obese and lean rats
105. Acute and chronic losartan administration: Effect on angiotensin II content and modulation of [3H]norepinephrine release from rat interscapular brown adipose tissue
106. Role of angiotensin II in brown adipose thermogenesis during cold acclimation
107. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness
108. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: Evidence for a regulatory role of endothelin
109. Molecular biology and biochemistry of the natriuretic peptide system. I. Natriuretic peptides
110. Natriuretic peptides
111. Molecular biology and biochemistry of the natriuretic peptide system. II. Natriuretic peptide receptors
112. Atrial natriuretic peptide inhibits mitogen-activated protein kinase through the clearance receptor. Potential role in the inhibition of astrocyte proliferation
113. Salt-sensitive hypertension in ANP knockout mice: Potential role of abnormal plasma 0renin activity
114. ANP in regulation of arterial pressure and fluid-electrolyte balance: Lessons from genetic mouse models
115. Transforming growth factor alpha and atrial natriuretic peptide in white adipose tissue depots in rats
116. Localization of atrial natriuretic factor receptors in the mesenteric arterial bed. Comparison with angiotensin II and endothelin receptors
117. Comparative analysis of atrial natriuretic peptide receptor expression in rat tissues
118. Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue
119. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients
120. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives
121. Effect of experimental obesity and subsequent weight reduction upon circulating atrial natriuretic peptide
122. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives
123. A review of the microcirculation of adipose tissue: Anatomic, metabolic, and angiogenic perspectives
124. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised
125. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
126. Genetic variation on chromosome 1 associated with variation in body fat distribution in men
127. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity
128. Body fat, resting and exercise blood pressure and the angiotensinogen M235T polymorphism: The heritage family study
129. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II
130. Angiotensinogen gene polymorphism near transcription start site and blood pressure: Role of a T-to-C transition at intron I